Table of Contents
Thrombosis
Volume 2015 (2015), Article ID 414523, 6 pages
http://dx.doi.org/10.1155/2015/414523
Clinical Study

Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study

1Northwestern Memorial Hospital, 251 E. Huron Street, Chicago, IL 60611, USA
2Seton Northwest Hospital, 11113 Research Boulevard, Austin, TX 78759, USA
3University Medical Center Brackenridge, 601 East 15th Street, Austin, TX 78701, USA
4Seton Medical Center Williamson, 201 Seton Parkway, Round Rock, TX 78665, USA
5Seton Medical Center Austin, 1201 West 38th Street, Austin, TX 78705, USA

Received 28 August 2015; Accepted 6 December 2015

Academic Editor: Cees Vermeer

Copyright © 2015 Kirsten M. Roberts et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Dalen, “Pulmonary embolism: what have we learned since virchow?: treatment and prevention,” Chest, vol. 122, no. 5, pp. 1801–1817, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. M. G. Beckman, W. C. Hooper, S. E. Critchley, and T. L. Ortel, “Venous thromboembolism: a public health concern,” American Journal of Preventive Medicine, vol. 38, supplement, no. 4, pp. S495–S501, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Ageno, A. S. Gallus, A. Wittkowsky, M. Crowther, E. M. Hylek, and G. Palareti, “Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2, supplement, pp. e44S–e88S, 2012. View at Publisher · View at Google Scholar
  4. D. W. Barritt and S. C. Jordan, “Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial,” The Lancet, vol. 275, no. 7138, pp. 1309–1312, 1960. View at Publisher · View at Google Scholar · View at Scopus
  5. H. R. Büller, M. H. Prins, A. W. A. Lensing et al., “Oral rivaroxaban for the treatment of symptomatic pulmonary embolism,” The New England Journal of Medicine, vol. 366, no. 14, pp. 1287–1297, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Schulman, A. K. Kakkar, S. Z. Goldhaber et al., “Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis,” Circulation, vol. 129, no. 7, pp. 764–772, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Agnelli, H. R. Buller, A. Cohen et al., “Oral apixaban for the treatment of acute venous thromboembolism,” The New England Journal of Medicine, vol. 369, no. 9, pp. 799–808, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. H. R. Büller, H. Décousus, M. A. Grosso et al., “Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism,” The New England Journal of Medicine, vol. 369, no. 15, pp. 1406–1415, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Lin, R. Preblick, M. Lingohr-Smith, and W. J. Kwong, “Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective,” Journal of Managed Care Pharmacy, vol. 20, no. 2, pp. 174–186, 2014. View at Google Scholar · View at Scopus
  10. C. E. Mahan, M. E. Borrego, A. L. Woersching et al., “Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates,” Thrombosis and Haemostasis, vol. 108, no. 2, pp. 291–302, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. A. C. Spyropoulos and J. Lin, “Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations,” Journal of Managed Care Pharmacy, vol. 13, no. 6, pp. 475–486, 2007. View at Google Scholar · View at Scopus
  12. F. Laliberté, D. Pilon, M. K. Raut et al., “Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?” Current Medical Research and Opinion, vol. 30, no. 4, pp. 645–653, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. B. van Bellen, L. Bamber, F. Correa De Carvalho, M. Prins, M. Wang, and A. W. A. Lensing, “Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism,” Current Medical Research and Opinion, vol. 30, no. 5, pp. 829–837, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. B. K. Bookhart, L. Haskell, L. Bamber, M. Wang, J. Schein, and S. H. Mody, “Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program,” Journal of Medical Economics, vol. 17, no. 10, pp. 691–695, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. K. K. Knight, J. Wong, O. Hauch, G. Wygant, D. Aguilar, and J. J. Ofman, “Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients,” Value in Health, vol. 8, no. 3, pp. 191–200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. J. F. Dasta, D. Pilon, S. H. Mody et al., “Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy,” Thrombosis Research, vol. 135, no. 2, pp. 303–310, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. A. A. Patel, K. Ogden, S. H. Mody, and B. Bookhart, “The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism,” Journal of Medical Economics, vol. 18, no. 5, pp. 323–332, 2015. View at Publisher · View at Google Scholar